U.S. Markets closed
  • S&P Futures

    3,657.25
    +34.00 (+0.94%)
     
  • Dow Futures

    29,900.00
    +271.00 (+0.91%)
     
  • Nasdaq Futures

    12,386.75
    +109.75 (+0.89%)
     
  • Russell 2000 Futures

    1,843.20
    +23.10 (+1.27%)
     
  • Crude Oil

    44.98
    -0.36 (-0.79%)
     
  • Gold

    1,787.80
    +6.90 (+0.39%)
     
  • Silver

    22.94
    +0.35 (+1.56%)
     
  • EUR/USD

    1.1962
    +0.0027 (+0.2273%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3359
    +0.0027 (+0.2031%)
     
  • USD/JPY

    104.4270
    +0.1030 (+0.0987%)
     
  • BTC-USD

    19,554.56
    +44.68 (+0.23%)
     
  • CMC Crypto 200

    383.84
    +19.24 (+5.28%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,812.41
    +378.79 (+1.43%)
     

Return On Capital Employed Overview: Seres Therapeutics

Benzinga Insights
·2 min read

During Q2, Seres Therapeutics (NASDAQ: MCRB) reported sales totaled $6.04 million. Despite a 4.33% in earnings, the company posted a loss of $20.55 million. In Q1, Seres Therapeutics brought in $8.19 million in sales but lost $19.69 million in earnings.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Seres Therapeutics posted an ROCE of 0.31%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on MCRB

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Seres Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.

In Seres Therapeutics's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q2 Earnings Insight

Seres Therapeutics reported Q2 earnings per share at $-0.28/share, which did not meet analyst predictions of $-0.26/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.